10 PHARMACEUTICAL-GRADE OPERATING STANDARDS
Olympia Biosciences™ operates as your external pharmaceutical R&D institution. Every formula engineered from molecular first principles. Every batch validated to PPQ standards. 100% IP ownership transferred unconditionally to you.
MANDATE QUALIFICATION
Our 17-year zero-complaint record is not accidental. It is the result of admitting only mandates where scientific rigor, ownership discipline, and regulatory commitment can be verified before a single milligram is formulated.
REJECTION CRITERIA
ADMISSION GATE
No Free Scoping. No Speculative Pipeline. No Commodity Orders.
The paid due diligence gate is mandatory. It protects current partners from bandwidth dilution and ensures every project entering the lab meets our scientific bar.
ADMISSION REQUIREMENTS
OPERATING SPECIFICATIONS
These are not differentiators against a commodity benchmark. They are the minimum operating specifications of a pharmaceutical R&D institution that builds client IP as its only business.
OLYMPIA SPECIFICATION
Custom Formulation: 100% permanent IP transfer — full formula rights, manufacturing documentation, and source material specifications belong to you from day one.
CLIENT STRATEGIC OUTCOME
You build proprietary technological assets that increase company valuation and create defensible barriers to competitive entry.
OLYMPIA SPECIFICATION
Evidence-Based Sourcing: Every active ingredient is selected based on the most current peer-reviewed clinical data for bioavailability and efficacy — not warehouse availability.
CLIENT STRATEGIC OUTCOME
Your product leads market trends rather than following them. Defensible clinical claims. Faster premium market positioning.
OLYMPIA SPECIFICATION
Process Performance Qualification: Every scale-up validated to Cpk >1.33 pharmaceutical standard. Controlled technology transfer from bench to millions of units with documented reproducibility.
CLIENT STRATEGIC OUTCOME
Operational certainty: mathematically guaranteed batch-to-batch reproducibility. Zero failed production runs across 350+ launches.
OLYMPIA SPECIFICATION
Zero Conflict Architecture: No consumer brands — ever. Formula know-how protected under audited ISO 27001:2023 information security. The same framework used by financial institutions.
CLIENT STRATEGIC OUTCOME
Complete, permanent protection against IP cannibalization by your own manufacturer. ISO 27001 audited by POLCARGO GROUP Ltd.
OLYMPIA SPECIFICATION
Full regulatory architecture: EU GIS notification, EFSA health claims, U.S. FDA procedures (U.S. Agent), export documentation (FSC). We navigate every market. You focus on the science.
CLIENT STRATEGIC OUTCOME
Zero regulatory exposure. Market entry protected. Ready to scale into U.S., EU, APAC, and MENA markets from day one.
OLYMPIA SPECIFICATION
Proprietary AI: After scientists complete formulation, our AI system performs predictive interaction mapping, multi-component matrix kinetics analysis, and toxicological risk screening across every ingredient combination.
CLIENT STRATEGIC OUTCOME
Mathematical certainty of optimized bioavailability and safety. A mandatory verification step that exists at no other European CDMO.
OLYMPIA SPECIFICATION
Direct Integration: Strategic partnership with Eklavya Biotech (India) — controlling botanical extracts directly at source. No intermediary supply chain contamination risk.
CLIENT STRATEGIC OUTCOME
Margin protection through intermediary elimination. Guaranteed provenance documentation. Heavy metals and contamination risk controlled at source.
OLYMPIA SPECIFICATION
Exclusive Technology Access: Vegicoll® (world's first plant-based collagen analog with hydroxyproline, TM Z.566783) and exclusive Cambridge-partnered micellar technology — unavailable anywhere else.
CLIENT STRATEGIC OUTCOME
Category pioneer status: competitors cannot replicate your product. Defensible market position backed by registered technology and documented partnerships.
OLYMPIA SPECIFICATION
Paid Discovery: A dedicated R&D phase fully deductible from the production invoice. Ends with a scientifically validated Proof of Concept and complete feasibility report.
CLIENT STRATEGIC OUTCOME
Capital certainty: hard scientific evidence of efficacy and stability before committing to full-scale production investment.
OLYMPIA SPECIFICATION
Science First: CEO is a technical physicist and doctoral candidate in medical sciences. Total Quality Management (TQM) culture across all operations. Every decision is made by scientists.
READ: SCIENCE-FIRST MANIFESTO →CLIENT STRATEGIC OUTCOME
A B2B partnership with experts who understand the molecular biophysics of your formulation — not sales managers optimizing for volume.
SCIENTIFIC DIRECTOR STATEMENT
“In advanced contract manufacturing, trust is not built on promises — it is built on precise, measurable process reproducibility. Our entire intellectual capital works exclusively to build the assets of your company. We do not compete with our clients — we arm them technologically.”
OLIMPIA BARANOWSKA
CEO & SCIENTIFIC DIRECTOR — IOC LTD.
ENTERPRISE PARTNER ENTRY
Initiate a Paid Discovery audit. Our R&D team verifies technology feasibility, scale-up protocols, and CAPEX budgets before full production — protecting your capital from day one. The fee is 100% deductible from your first production invoice.
RELATED INTELLIGENCE
Strictly B2B / Educational R&D Disclaimer
The pharmacokinetic data, clinical references, and scientific literature referenced on this page are provided strictly for B2B formulation, educational, and R&D purposes for medical professionals, pharmacologists, and brand developers. Olympia Biosciences™ operates solely as a Contract Development and Manufacturing Organization (CDMO) and does not manufacture, market, or sell consumer end-products.
Global Regulatory & No Health Claims. Nothing on this page constitutes a health claim, medical claim, or disease-risk-reduction claim within the meaning of EU Regulation (EC) No 1924/2006, the U.S. Dietary Supplement Health and Education Act (DSHEA), or other global regulatory frameworks. These statements and raw data have not been evaluated by the Food and Drug Administration (FDA), European Food Safety Authority (EFSA), or Therapeutic Goods Administration (TGA). The raw active pharmaceutical ingredients (APIs) and formulations discussed are not intended to diagnose, treat, cure, or prevent any disease.
Client Responsibility. The B2B client who commissions a formulation from Olympia Biosciences™ bears full and sole responsibility for all regulatory compliance, health claim authorization (including EFSA Article 13/14 claim dossiers and U.S. FDA notifications), labeling, and marketing of their finished product in their target market(s). Olympia Biosciences™ provides manufacturing, formulation, and analytical services only.